Novo Nordisk receives FDA approval for Norditropin® FlexPro® for growth hormone treatment

Novo NordiskNovo Nordisk announced that the US Food and Drug Administration (FDA) has approved Norditropin® FlexPro®, a new prefilled growth hormone injection pen to be used by children and adults.

Norditropin® FlexPro® has a unique new dosing mechanism, a user-friendly design which makes it easy to learn and use, and an audible click that confirms that the dose has been delivered. Norditropin® FlexPro® requires no reconstitution and no loading of cartridges. Norditropin® FlexPro® is available in 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml pens.

In a handling study[1], 100% of patients found it easy to learn how to use Norditropin® FlexPro®. Ninety-nine percent of patients found it easy to push the button to dose, and 97% felt confident the correct dose was delivered.

"During our 20 years providing Norditropin® growth hormone, we have listened to patients and we understand the importance of providing simple, hassle-free patient care," says Pablo de Mora, global vice president of Growth Hormone Treatment in Novo Nordisk. "With the advantages of our new Norditropin® FlexPro® we are convinced that daily injections will be made even simpler, so patients are better able to achieve their individual treatment goals."

Novo Nordisk introduced Norditropin® in 1988; the first liquid growth hormone formulation, Norditropin® SimpleXx®, in 1999; and the first prefilled growth hormone pen, Norditropin NordiFlex®, in 2004. The introduction of Norditropin® FlexPro® represents the latest advance in growth hormone pens building on this heritage.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

1. Fuchs GS et al. Clin Ther 2009; 31 (12)

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...